A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B
FNs are high-molecular-mass adhesive glycoproteins (for reviews see 3, 11, 12) and EDB (a complete type III repeat, extra domain B) (Fig. 1) . For EDA and EDB exon usage or skipping leads to inclusion or exclusion of these type III repeats. In cultured transformed cells and in malignancies, the splicing pattern of FN pre-mRNA is altered,4,5,7,9,10,15-18 leading to an increased expression of FN isoforms containing the domains regulated by alternative splicing. In particular, the B-FN, which, with some very rare exceptions, is undetectable in normal adult tissues, exhibits a much greater expression in fetal and tumor tissues, as well as during wound healing. 5, 16, 19, 20 Furthermore, B-FN is accumulated around neovasculature during angiogenic processes21,22 and thereby provides a marker for angiogenesis. The generation of a monoclonal antibody (mAb), BC1, highly specific for the human B-FN isoform,5 has allowed all of the early extensive immunohistochemical studies that have clearly established the outstanding presence of B-FN in different kinds of pathologies, including various forms of cancer and all angiogenesisassociated pathologies.18,22 However, this antibody does not recognize an epitope within the EDB, but one localized on the type III repeat 7 that precedes the EDB (Fig. 1) . This epitope is cryptic in FN molecules lacking the EDB and unmasked in molecules containing this domain.23 A mAb, IST6, was also generated that is highly specific for EDB-free FN and thus does not react with B-FN. Using these 2 mAbs, we demonstrated that the insertion of the EDB in FN molecules leads to a conformational modification that unmasks hindered sequences and hinder other sequences. 23 Here, we now report on a novel sequence localized on the type III repeat 8 (the one immediately downstream of the EDB, Fig. 1 ), which is cryptic when the EDB is omitted and unmasked when it is included within the FN molecule. We also describe a high-affinity murine monoclonal antibody, C6, specific for this epitope. Using the cloned variable regions of this mAb, we produced a divalent, covalently bound mini-antibody and demonstrated its ability to target B-FN in vivo in tumorbearing mice.
Material and methods

Monoclonal antibodies
mAbs specific for human FN were prepared as previously described24 by fusion of SP2/0 murine myeloma cells (ATCC, American Type Culture Collection, Rockville, MD) with splenocytes from immunized Balb/C mice (Charles River, Italy). ELISA, SDS-PAGE, Western blotting and size exclusion chromatography were performed as described. 25 The mAb BC1 and the human recombinant antibody CGS1 have been previously described.5,23,26 The Mab BC1 recognizes B-FN reacting with a cryptic epitope on the repeat III7 unmusked when EDB is inserted into the FN molecule. The recombinant single-chain variable fragment (scFv) CGS1 reacts directly with EDB.
The binding properties of the mAb C6 to the FN recombinant fragment 7.EDB.8.9 were studied by real-time interaction analysis with surface plasmon resonance detection using a BIAcore 1000 instrument (Biacore AB, Uppsala, Sweden) as previously reported by Tarli et al.27 Purification of plasma and cellular FNs and FN recombinant fragments FN was purified as previously described16 from human plasma and from conditioned media of SV40-transformed human fibroblasts WI38VA grown in Eagle's minimum-essential medium supplemented with 10% fetal calf serum (FCS) (Flow Laboratories, Irvine, Scotland, UK), depleted of bovine FN by passage through a large capacity gelatin-Sepharose column (GE Healthcare BioSciences, Milan, Italy). Recombinant FN fragments containing various FN type III homology repeats ( Fig. 1) were produced by PCR using the DNA clones FNIII 2-11 (ED-B1) and FNIII 2-11 (ED-B-), previously described,26 as template and appropriate primers. PCR products were cloned into the pQE-12 vector using the QIAexpress kit and expressed in M15 competent bacteria cells. All cloned cDNAs were sequenced on both strands. Recombinant proteins were purified by Ni-NTA columns (Qiagen, Hilden, Germany) by use of the His6 tag appended at the C-terminus of the FN fragments, according to the manufacturer's instructions.
Tissues and immunohistochemical procedures
Normal and neoplastic human tissues were obtained from samples taken during the course of therapeutic surgical procedures. Specimens of the F9 murine teratocarcinoma and of the human melanoma SKMEL-28 (ATCC) were obtained by subcutaneous injection with 2 3 106 cells in 6-week-old SCID Beige SPF/VAF mice. Animals were sacrificed when tumors reached a diameter of about 1.0 cm. SCID Beige SPF/VAF mice were used to avoid background in immunohistochemical experiments because of endogenous immunoglobulins. The immunohistochemical procedure was performed as previously described.21 A biotinylated goat antimouse IgG (Bio-SPA, Milan) was used as secondary antibody for murine monoclonal antibodies BC1 and C6, whereas for the recombinant antibody CGS1, we used the anti Myc-tag 9E10 murine monoclonal antibody (ATCC) followed by the biotinylated goat anti-mouse IgG. For negative controls, the primary antibodies were replaced by PBS or additioned with an excess of antigen (7.EDB.8.9).
Preparation of the C6-UG fusion protein (mini-antibody)
Total RNA was purified using the procedure reported by Chomczynski and Sacchi. 28 The cDNA of the variable regions of C6 mAb was obtained by RT-PCR using total RNA purified from C6 hybridoma cells, as template, and the primers: 50gatattgtgatga cccagtctcca30 (fw) and supplemented with 10% FCS (Biochrom AG, Berlin, Germany) and 4 mM L-glutamine (Invitrogen), and selected using 500 lg/ml of Geneticin (G418, Calbiochem, San Diego, CA). The supernatants of the G418 resistant clones were screened for the production of the fusion proteins by ELISA using the recombinant fragment 7.EDB.8.926 as antigen (for C6-UG). A rabbit polyclonal anti-mouse UG antibody, produced in our laboratories, was used as secondary antibody, and a peroxidase-conjugated anti-rabbit polyclonal IgG (Pierce, Rockford, IL) as tertiary antibody. The C6-UG fusion protein was immunopurified from the conditioned medium of the cells on 7.EDB.8.9
conjugated to CNBr-activated Sepharose 4B and analyzed in native conditions by fast protein liquid chromatography on a Superdex200 column and by SDS-PAGE under reducing and nonreducing conditions.
Radioiodination and biodistribution experiments using the fusion protein C6-uteroglobin
C6-UG was radioiodinated as previously described25 with iodine 125 using the Iodogen method (Pierce). After labeling, the immunoreactivity of the fusion protein was more than 90%. Nu/ Nu nude mice (Charles River, Italy) with subcutaneously implanted SKMEL28 human melanoma were injected intravenously with about 5 lg (4 lCi; 0.148 MBq) of protein in 100 ll saline solution. Three animals were used for each time point. Mice were sacrificed at 4, 24, 48 and 96 hr after injection.
The organs including tumor were weighed and the radioactivity was counted in a gamma counter.
Targeting results are expressed as a percent of the injected dose per gram of tissue (%ID/g).
Housing, treatment and sacrifice of animals followed national legislative provisions (Italian law no.
116 of 27 January, 1992). 
Results
Immunohistochemical studies
Using the mAb C6, we carried out immunohistochemical studies on cryostat sections of specimens from normal adult human tis-sues (breast, heart, oesophagus, muscle, thymus, spleen, thyroid, nerve, brain, testis, liver, parotid and lymph node), from human cancer (mesothelioma, melanoma, lung adenocarcinoma and glioblastoma) and from murine experimental tumors. We found that, identically to the results obtained with the mAbs BC1 and CGS1 (a human recombinant antibody that reacts directly with the EDB),26 all the normal human tissues tested were negative, whereas the human neoplastic tissues were strongly positive (Fig. 2) . These 3 antibodies reacted with identical structures in neoplastic tissues, with the exception of the F9 murine teratocarcinoma, in which CGS1 was the only antibody to react; the other 2 mAbs, BC1 and C6, were negative (Fig. 3) . This occurs because CGS1 directly recognizes the EDB, which is identical in human and mouse, thus ensuring its reaction equally well with human and mouse B-FN. In contrast, C6 and BC1 react with human specific epitopes on repeats III8 and III7, respectively, and consequently do not recognize murine B-FN.
Generation of the C6 mini-antibody
IgGs are large molecules and their penetration in tissues is poor. We therefore generated a C6 miniantibody to evaluate tumor targeting in tumor-bearing mice. The cDNA variable regions VH and VL of the mAb C6 were cloned as reported in Material and methods and sequenced on both strands.
Using the 2 variable regions, we generated a scFv and attempted to construct a SIP25 by ligating the scFv to the CH4 of the secretory isoform S2 of human IgE. Because of the very low solubility of the C6 SIP format, we generated a novel fusion protein with murine UG, a small and extremely soluble homodimeric protein.31,32 As described in the Material and methods section, we prepared the cDNA construct of C6-UG, depicted in Figure 4b , and transfected CHO cells. Figure 4a depicts the C6-UG molecule. This fusion protein, expressed in cultured CHO cells at about 4 mg/l, presented a very good solubility, stability and absence of aggregate formation at concentrations higher than 2 mg/ml. In addition, it was possible to lyophilize and reconstitute this protein without any loss of protein or immunoreactivity (data not shown). Figure 4c shows an SDS-PAGE of the purified C6-UG fusion protein. In SDS-PAGE, the protein migrates as a homodimer, in nonreducing conditions and as a monomer, in reducing conditions, with the expected sizes of about 75 and 38 kDa, respectively. The results demonstrated that in nonreducing conditions the protein is a 100% covalently linked homodimer, and the size exclusion chromatography profiles (Fig. 4d) showed a single peak with a retention volume corresponding to the molecular mass of the homodimer. Tumor targeting experiments were carried out in tumor-bearing mice using radioiodinated C6-UG and the human melanoma SKMEL28. 31, 32) . Using this approach, we were able to generate a very stable and very soluble covalently bound divalent C6. On the basis of this experience, we prepared other scFv fusion proteins using UG as a central skeleton, and we were able to prepare bivalent, tetravalent and dual-specific tetravalent molecules all with good solubility and stability (Sassi et al., manuscript in preparation). Tumor targeting was investigated through biodistribution studies by injecting radioiodinated C6-UG in tumor-bearing mice. The %ID/g of the tumor was lower compared to the ratio produced by the SIP format of L19 in the same tumor, but the residence time of radiolabeled C6-UG was longer: in fact, 4 days after injection, the amount of the radiolabeled protein in the tumor was only about 20% lower than it was 4 hr after injection, whereas the amount of the L19-SIP 4 days after injection was nearly 4 times lower compared to the %ID/g at 4 hr. At present, we cannot explain such a long and stable residence time, but it was reported that the EDB, with which L19 reacts, is very sensitive to various proteolytic enzymes, whereas the repeat III8 is much more stable.16 Therefore, the higher residence time in the tumor of C6 compared to L19 could be due to the differing resistance of the 2 epitopes, or of the flanking sequences, to proteolytic enzymes. The lower amount of C6 accumulating in the tumor with respect to L19-SIP could be explained by the fact that the B-FN in the experimental tumor model used human melanoma SKMEL28, originated in a small percentage from human tumor cells but the majority from the murine cells of the host such as fibroblasts, endothelial cells and other stroma cells. Because L19 is able to bind both human and mouse B-FN, whereas C6 can bind only the human B-FN present in the tumor, this could explain the lower C6-UG accumulation in the tumor with respect to L19-SIP. In conclusion, the mAb C6 represents a new tool for the study of the potential biological functions of hindered sequences that the inclusion of the EDB makes accessible.
Its epitope, moreover, provides an additional and stable angiogenesis target.
